Single-arm phase II study of low-dose paclitaxel and pembrolizumab in platinum-refractory metastatic urothelial carcinoma (UC).

被引：2
|
作者：
Bitting, Rhonda L. [1 ]
Vile, Donald Charles [2 ]
Tooze, Janet A. [3 ]
Thomas, Christopher Y. [1 ]
Neve, Morgan [1 ]
Kooshki, Mitra [1 ]
Brown, Jessica [4 ]
Dubey, Purnima [4 ]
Triozzi, Pierre [1 ]
Goodman, Michael Moses [1 ]
机构：
[1] Wake Forest Baptist Hlth, Ctr Comprehens Canc, Winston Salem, NC USA
[2] Wake Forest Baptist Hlth, Winston Salem, NC USA
[3] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA
[4] Ohio State Univ, Pelotonia Inst Immunooncol, James Comprehens Canc Ctr, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.433
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
433
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer
    Yamamoto, Shigeru
    Maeda, Noriko
    Nagashima, Yukiko
    Kubo, Hidefumi
    Sato, Yoko
    Matsui, Hiroto
    Inoue, Yuka
    Shindo, Yoshitaro
    Kanekiyo, Shinsuke
    Sakamoto, Kazuhiko
    Suzuki, Nobuaki
    Takeda, Shigeru
    Ueno, Tomio
    Yoshino, Shigefumi
    Hazama, Shoichi
    Oka, Masaaki
    Nagano, Hiroaki
    BREAST CANCER, 2017, 24 (06) : 783 - 789
  • [22] Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
    Sharma, Padmanee
    Retz, Margitta
    Siefker-Radtke, Arlene
    Baron, Ari
    Necchi, Andrea
    Bedke, Jens
    Plimack, Elizabeth R.
    Vaena, Daniel
    Grimm, Marc-Oliver
    Bracarda, Sergio
    Arranz, Jose Angel
    Pal, Sumanta
    Ohyama, Chikara
    Saci, Abdel
    Qu, Xiaotao
    Lambert, Alexandre
    Krishnan, Suba
    Azrilevich, Alex
    Galsky, Matthew D.
    LANCET ONCOLOGY, 2017, 18 (03): : 312 - 322
  • [23] A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck
    Bossi, P.
    Merlano, M. C.
    Ghi, M. G.
    Rinaldi, G.
    Caponigro, F.
    Morelli, F.
    Airoldi, M.
    Farnesi, A.
    Cassano, A.
    Ferrari, D.
    Mirabile, A.
    Tosoni, A.
    Galizia, D.
    Moretti, G.
    Sponghini, A. P.
    Calareso, G.
    Vingiani, A.
    Perrone, F.
    Falletta, A.
    Licitra, L. F.
    ANNALS OF ONCOLOGY, 2019, 30 : 463 - 463
  • [24] A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma (UC)
    Matsubara, Nobuaki
    Petrylak, Daniel Peter
    Nishiyama, Hiroyuki
    Su, Wen-Pin
    Lee, Jae-Lyun
    Li, Jian-Ri
    Walgren, Richard A.
    Hamid, Oday
    Zimmermann, Annamaria
    Bell-McGuinn, Katherine M.
    Gao, Ling
    Homma, Gosuke
    Yana, Ikuo
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study
    Lan, Chun-Yan
    Wang, Yin
    Xiong, Ying
    Li, Jun-Dong
    Shen, Jing-Xian
    Li, Yan-Fang
    Zheng, Min
    Zhang, Yan-Na
    Feng, Yan-Ling
    Liu, Qing
    Huang, Hui-Qiang
    Huang, Xin
    LANCET ONCOLOGY, 2018, 19 (09): : 1239 - 1246
  • [26] A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma (RCC).
    Rosenberg, J. E.
    Drabkin, H. A.
    Lara, P., Jr.
    Harzstark, A. L.
    Figlin, R. A.
    Smith, G. W.
    Erlandsson, F.
    Laber, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU)
    Vaughn, D. J.
    Srinivas, S.
    Stadler, W. M.
    Pili, R.
    Petrylak, D.
    De Marco, S.
    Smith, D. C.
    Nason, S.
    De Wit, E.
    George, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urotheliurn (TCCU)
    George, C.
    Vaughn, D. J.
    Petrylak, D.
    Srinivas, S.
    Pili, R.
    Stadler, W.
    De Marco, S.
    Smith, D. C.
    Nason, S.
    De Wit, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 309 - 309
  • [29] A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma
    Bauman, Julie E.
    Arias-Pulido, Hugo
    Lee, Sang-Joon
    Fekrazad, M. Houman
    Ozawa, Hiroyuki
    Fertig, Elana
    Howard, Jason
    Bishop, Justin
    Wang, Hao
    Olson, Garth T.
    Spafford, Michael J.
    Jones, Dennie V.
    Chung, Christine H.
    ORAL ONCOLOGY, 2013, 49 (05) : 461 - 467
  • [30] Phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC)
    Gallagher, D. J.
    Milowsky, M. I.
    Gerst, S. R.
    Iasonos, A.
    Riches, J.
    Boyle, M. G.
    Bajorin, D. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345